肺癌和慢性阻塞性肺疾病患者的局部和全身中性粒细胞炎症。
Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease.
机构信息
Department of Pulmonology and Immunology, Medical Academy, Hospital of Lithuanian University of Health Sciences, Eiveniu 2, Kaunas LT-50028, Lithuania.
出版信息
BMC Immunol. 2013 Aug 6;14:36. doi: 10.1186/1471-2172-14-36.
BACKGROUND
Recent investigations suggest that neutrophils play an important role in the immune response to lung cancer as well as chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate the amount of neutrophils and markers of their activity in lung cancer and COPD and in coexistence of these two diseases.
METHODS
In total, 267 persons were included in the study: 139 patients with lung cancer, 55 patients with lung cancer and COPD, 40 patients with COPD, and 33 healthy subjects. Peripheral blood and BAL fluid samples were obtained for cell count analysis and determination of NE, MPO levels and ROS production. NE and MPO levels in the serum and BAL fluid were determined by ELISA. ROS production was analyzed by flow cytometer.
RESULTS
The percentage, cell count of neutrophils and neutrophil to lymphocyte ratio in the peripheral blood were significantly higher in lung cancer patients with or without COPD compared to COPD patients or healthy individuals (P < 0.05). The percentage and cell count of neutrophils in BAL fluid were significantly lower in patients with lung cancer with or without COPD than in patients with COPD (P < 0.05). However, BAL fluid and serum levels of both NE and MPO were significantly higher in patients with lung cancer than COPD patients or healthy individuals (P < 0.05). Neutrophils produced higher amounts of ROS in patients with lung cancer with or without COPD compared with COPD patients or healthy individuals (P < 0.05).
CONCLUSIONS
The results from this study demonstrate higher degree of local and systemic neutrophilic inflammation in patients with lung cancer (with or without COPD) than in patients with COPD.
背景
最近的研究表明，中性粒细胞在肺癌以及慢性阻塞性肺疾病（COPD）的免疫反应中发挥重要作用。本研究旨在评估肺癌和 COPD 患者以及同时患有这两种疾病的患者体内中性粒细胞数量及其活性标志物的水平。
方法
本研究共纳入 267 名患者，包括 139 名肺癌患者、55 名肺癌合并 COPD 患者、40 名 COPD 患者和 33 名健康对照者。采集外周血和 BAL 液样本进行细胞计数分析，并测定中性粒细胞弹性蛋白酶（NE）、髓过氧化物酶（MPO）水平和活性氧（ROS）的产生。采用 ELISA 法检测血清和 BAL 液中 NE 和 MPO 的水平，通过流式细胞仪分析 ROS 的产生。
结果
与 COPD 患者或健康对照者相比，肺癌伴或不伴 COPD 患者的外周血中性粒细胞百分比、细胞计数和中性粒细胞与淋巴细胞比值显著更高（P < 0.05）。肺癌伴或不伴 COPD 患者的 BAL 液中中性粒细胞百分比和细胞计数显著低于 COPD 患者（P < 0.05）。然而，肺癌伴或不伴 COPD 患者的 BAL 液和血清中 NE 和 MPO 水平显著高于 COPD 患者或健康对照者（P < 0.05）。肺癌伴或不伴 COPD 患者的中性粒细胞产生的 ROS 量显著高于 COPD 患者或健康对照者（P < 0.05）。
结论
本研究结果表明，肺癌（伴或不伴 COPD）患者的局部和全身中性粒细胞炎症程度高于 COPD 患者。
Zotero 插件